It's a year late, but No­var­tis has fi­nal­ly steered in­clisir­an to FDA ap­proval. Will it sell?

4 years ago
Pharma
FDA+

Covid-19 roundup: No­vavax says vac­cine shows 'broad cross-re­ac­tiv­i­ty' against Omi­cron; France can­cels or­der on ...

4 years ago
Coronavirus

No­var­tis taps Roche's neu­ro and rare dis­ease re­search lead to run neu­ro­science re­search

4 years ago
People
R&D

Joan Shen ends the year by say­ing good­bye to I-Mab; CRISPR Ther­a­peu­tics puts coal in R&D chief's stock­ing

4 years ago
Peer Review

FDA au­tho­rizes the first at-home pills from Pfiz­er to treat Covid-19

4 years ago
FDA+
Coronavirus

Months af­ter miss­ing its PDU­FA date, FDA slaps down Takeda's old Shire drug for eosinophilic esophagi­tis

4 years ago
FDA+

Biotech vets jump on board a start­up, raise cash and take aim at the clin­ic with an­ti-in­flam­ma­to­ry drugs

4 years ago
Financing

Al­lakos drops a pair of duds on pa­tient-re­port­ed symp­tom re­lief for GI dis­ease, va­por­iz­ing bil­lions off its val­ue

4 years ago
R&D

Boston start­up lands $28M, clos­es small biotech buy­out; New longevi­ty fund takes shape

4 years ago
News Briefing

Covid-19 roundup: Ques­tions re­main on US sup­plies of Pfiz­er, Mer­ck pills as UK ramps up; Is­rael to go for a fourth ...

4 years ago
Coronavirus

Bio­gen ex­tends its set­back streak as Japan­ese reg­u­la­tors push back against their con­tro­ver­sial Alzheimer's drug

4 years ago
Pharma

‘Dis­ap­point­ing’ Vi­a­Cyte da­ta raise ques­tions about fu­ture of com­pa­ny’s at­tempt­ed di­a­betes cure

4 years ago
R&D
Cell/Gene Tx

FDA slaps a hold on Gilead­'s in­jectable HIV treat­ment over con­cerns about po­ten­tial glass con­t­a­m­i­nants

4 years ago
FDA+

'He re­peat­ed­ly lied': Feds pile on as Har­vard chemist Charles Lieber con­vict­ed of ly­ing about Chi­nese ties

4 years ago
People
China

No­var­tis un­wraps $1.5B gene ther­a­py buy­out — beef­ing up ar­se­nal against reti­nal dis­eases

4 years ago
Deals
Cell/Gene Tx

Q&A: From the CDC to Gilead Sci­ences, Rashad Burgess works lo­cal for na­tion­al change in HIV com­mu­ni­ty

4 years ago
Pharma
Marketing

Phar­ma mar­ket­ing 2022: More dig­i­tal shifts for reps, ads and drug launch­es, plus rep­u­ta­tion and the meta­verse

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: J&J tack­les racism in new on­line se­ries; GSK's Trel­e­gy asth­ma ads amp aware­ness

4 years ago
Pharma
Marketing

Bil­lion­aire Bob Dug­gan's new an­tibi­ot­ic play fails a Phase III tri­al, and in­vestors aren't hap­py

4 years ago
R&D

Covid-19 roundup: FDA to sign off on Mer­ck, Pfiz­er pills this week — re­port; Broad In­sti­tute finds rise of Omi­cron ...

4 years ago
Coronavirus

Am­gen's Ote­zla bags ex­pand­ed FDA nod in pso­ri­a­sis; I-Mab CEO hits the ex­it amid shake­up at Chi­nese firm

4 years ago
News Briefing

FDA slams clin­i­cal hold on tiny psy­che­delics play­er's shot at bring­ing LSD-as­sist­ed ther­a­py to more pa­tients

4 years ago
R&D
FDA+

Alzheimer's ex­perts call on FDA to pull Bio­gen's Aduhelm

4 years ago
Pharma
FDA+

With few treat­ment op­tions for Omi­cron, con­va­les­cent plas­ma is ready for a come­back — will the FDA be on board with ...

4 years ago
FDA+
Coronavirus
First page Previous page 605606607608609610611 Next page Last page
A service from the Financial Times